University Lyon 1, INRA UMR-754, Retrovirus & Comparative Pathology, 50, avenue Tony Garnier, 69366 Lyon Cedex 07, France.
BMC Biotechnol. 2010 Nov 19;10:80. doi: 10.1186/1472-6750-10-80.
Cells permissive to virus can become refractory to viral replication upon intracellular expression of single chain fragment variable (scFv) antibodies directed towards viral structural or regulatory proteins, or virus-coded enzymes. For example, an intrabody derived from MH-SVM33, a monoclonal antibody against a conserved C-terminal epitope of the HIV-1 matrix protein (MAp17), was found to exert an inhibitory effect on HIV-1 replication.
Two versions of MH-SVM33-derived scFv were constructed in recombinant baculoviruses (BVs) and expressed in BV-infected Sf9 cells, N-myristoylation-competent scFvG2/p17 and N-myristoylation-incompetent scFvE2/p17 protein, both carrying a C-terminal HA tag. ScFvG2/p17 expression resulted in an insoluble, membrane-associated protein, whereas scFvE2/p17 was recovered in both soluble and membrane-incorporated forms. When coexpressed with the HIV-1 Pr55Gag precursor, scFvG2/p17 and scFvE2/p17 did not show any detectable negative effect on virus-like particle (VLP) assembly and egress, and both failed to be encapsidated in VLP. However, soluble scFvE2/p17 isolated from Sf9 cell lysates was capable of binding to its specific antigen, in the form of a synthetic p17 peptide or as Gag polyprotein-embedded epitope. Significant amounts of scFvE2/p17 were released in the extracellular medium of BV-infected cells in high-molecular weight, pelletable form. This particulate form corresponded to BV particles displaying scFvE2/p17 molecules, inserted into the BV envelope via the scFv N-terminal region. The BV-displayed scFvE2/p17 molecules were found to be immunologically functional, as they reacted with the C-terminal epitope of MAp17. Fusion of the N-terminal 18 amino acid residues from the scFvE2/p17 sequence (N18E2) to another scFv recognizing CD147 (scFv-M6-1B9) conferred the property of BV-display to the resulting chimeric scFv-N18E2/M6.
Expression of scFvE2/p17 in insect cells using a BV vector resulted in baculoviral progeny displaying scFvE2/p17. The function required for BV envelope incorporation was carried by the N-terminal octadecapeptide of scFvE2/p17, which acted as a signal peptide for BV display. Fusion of this peptide to the N-terminus of scFv molecules of interest could be applied as a general method for BV-display of scFv in a GP64- and VSV-G-independent manner.
细胞对病毒的允许性可以通过细胞内表达针对病毒结构或调节蛋白或病毒编码酶的单链片段可变(scFv)抗体而变得对病毒复制产生抗性。例如,源自 MH-SVM33 的内体,这是一种针对 HIV-1 基质蛋白(MAp17)保守 C 末端表位的单克隆抗体,被发现对 HIV-1 复制具有抑制作用。
构建了两种 MH-SVM33 衍生的 scFv 在重组杆状病毒(BV)中,并在 BV 感染的 Sf9 细胞中表达,N-豆蔻酰化能力 scFvG2/p17 和 N-豆蔻酰化能力 scFvE2/p17 蛋白,都带有 C 末端 HA 标签。 scFvG2/p17 的表达导致不溶性、膜相关蛋白,而 scFvE2/p17 以可溶性和膜结合形式回收。当与 HIV-1 Pr55Gag 前体共表达时,scFvG2/p17 和 scFvE2/p17 对病毒样颗粒(VLP)组装和出芽没有显示出任何可检测的负效应,并且两者都不能被封装在 VLP 中。然而,从 Sf9 细胞裂解物中分离的可溶性 scFvE2/p17 能够以合成的 p17 肽或作为 Gag 多蛋白嵌入表位的形式与其特异性抗原结合。大量的 scFvE2/p17 以高分子量、可沉淀的形式在 BV 感染细胞的细胞外培养基中释放。这种颗粒形式对应于通过 scFv N 末端区域插入 BV 包膜的 BV 显示的 scFvE2/p17 分子。BV 显示的 scFvE2/p17 分子被发现具有免疫功能,因为它们与 MAp17 的 C 末端表位反应。将 scFvE2/p17 序列的 N 末端 18 个氨基酸残基(N18E2)融合到另一个识别 CD147 的 scFv(scFv-M6-1B9)上,使所得嵌合 scFv-N18E2/M6 具有 BV 显示的特性。
使用 BV 载体在昆虫细胞中表达 scFvE2/p17 导致显示 scFvE2/p17 的杆状病毒后代。BV 包膜掺入所需的功能由 scFvE2/p17 的 N 末端十八肽携带,该肽充当 BV 显示的信号肽。将该肽融合到感兴趣的 scFv 分子的 N 末端可以作为一种通用方法,用于在不依赖 GP64 和 VSV-G 的情况下在 BV 上显示 scFv。